Top Industry Leaders in the Atopic Dermatitis Market
Latest Atopic Dermatitis Companies Updates:
Dermavant Sciences receives U.S. Food and Drug Administration (FDA) approval for Vtama (tapinarof) cream for moderate-to-severe plaque psoriasis: This October 2023 development could potentially offer future opportunities for Vtama as a potential treatment option for atopic dermatitis, given its mechanism of action.
AbbVie announces positive Phase 3 results for upadacitinib in treating moderate-to-severe atopic dermatitis: This September 2023 update indicates potential for this JAK inhibitor to offer another effective treatment option for patients with atopic dermatitis.
Eli Lilly receives US regulatory approval for lebrikizumab for moderate-to-severe atopic dermatitis: This August 2023 milestone expands the availability of IL-13 inhibitor therapies for managing atopic dermatitis.
GlaxoSmithKline (GSK) releases the GALVANIZE study results suggesting positive outcomes for dupilumab (Dupixent) in treating chronic hand eczema associated with atopic dermatitis: This September 2023 research opens up a potential wider application of existing therapies for specific manifestations of atopic dermatitis.
Almirall launches Ekstar™ (calcipotriol/betamethasone dipropionate) foam in the US for the treatment of plaque psoriasis: While intended for psoriasis, this October 2023 launch might offer insights into potential future developments of foam-based formulations for atopic dermatitis treatment.
List of Atopic Dermatitis Key companies in the market:
- Astellas Pharma Inc. (Japan)
- Sanofi S.A. (France)
- Anacor Pharmaceuticals Inc. (U.S)
- Novartis International AG (Switzerland)
- Bristol-Myers Squibb (U.S)
- Meda Pharmaceuticals (U.S)
- Pfizer Inc. (U.S)